We would love to hear your thoughts about our site and services, please take our survey here.
Appreciate that Ripley, of course the update could be fully loaded rather than just ‘this is where things are’.
I thought about that and maybe it’s just hard for them to say until they have it all. I’ve no doubt the data report will be full by the science day.
The disappointment in the reading of yesterday’s RNS is the wording and the running order. The RNS leads with the science day and the pre clinical pipeline rather than leading with AVA6000 results first and then the preclinical pipeline.
Early Jan update is also down as an update, rather AV6000 clinical results. Not sure what we’ll get. So maybe another one before science day?
The results of AVA6000 are pretty fundamental to a lot of the pipeline so it doesn’t make sense chronologically. Maybe I’m overthinking.
It’s either that the results aren’t ready for one reason or another or it’s just a poorly considered piece of comms.
I still think, as many have said, the outcome will be robust, even though the comms still provide some ambiguity. They’ve never been great with their comms, apart from the last set around the fund raiser which were v solid.
With all the above said, If I could, I’d be piling in for double what I have. Sadly not able to after 3 sh it years.
Think the prospect is still amazing. It’s just, at times, I hate this Company and how they talk to us.
I am aswell but keep telling myself a watched pot never boils. What we have coming soon will be quite something.
Apologies, thank you Yorkshire, good find.
It’s worth logging into and reading. The research is about pharma heading over the cliff with LOE (Loss of exclusivity). Couple of bits below. Also features a chart of which big brands are heading out of patent and revenue impacts ‘over the Cliff’. Stuff on strategy & overcoming the magnitude of the looming problem.
From our point, it sets the scene well for the enormous opportunity Avacta may represent.
‘Investors are growing wary about the period from 2025-2030, when many big brands will
lose market exclusivity in the US and Europe and face generic or biosimilar competition for the first time.’
‘the total revenue loss by a couple of percentage points, from 46% to 44%, and you still have three companies losing over 50% of their revenues,” Whitman said.’
Excellent news. Can't see any possible negative side to this. It also brings welcome hope and possibility to those being recruited, with the benefit and experience of 400 days+ already done in the trial.
History in the making.
If it is us, (which I feel it is) and our trials have helped give rise to this news, the results could be beyond all expectations. What a day in the making!
It could be a good call otherwise presumably the II’s would be musing over the same questions, as would the one on one invitees. It would be hard to talk around direct questions relating to a long period of 1a.
Equally, knowing those questions would be forefront, why would you arrange this type of investors event?
Thanks Bella, all so worth waiting for. We’re on the verge of making scientific history. AVA6k soon to be the pathfinder for one treatment after another that were previously thought impossible.
It may take a few years for 10-12 products+ to hit the market but, from the short term and along the way, each will potentially bring huge revenues and ultimately, with Affirmers also breaking through, could make us the largest cap pharma in the market. I think that may also have been the Jeff Yass vision.
Fair assessment Wyndrum. I’m expecting nothing on Saturday but a thorough 1a, whenever it may be ready, is what we will get from high quality trial team who will put it together. It deserves to be verbatim and won’t need finessing by Avacta Comms.
All the evidence suggests the content will be extraordinary and as such should be preserved and communicated properly.
Avacta comms have generally been calamitous over the past couple of years, I think we know that. This time comms won’t matter.
They’d need to provide news in an RNS and most likely not at a weekend presentation. Most likely will still be very revealing and will be followed with structured news soon after.
31 October 2022
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at Virtual Theranostics FAP Summit
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that it will be presenting at the Theranostics FAP Summit, organised by the International Centers for Precision Oncology Foundation, being held on 5 November 2022.
The online meeting will feature world-renowned experts in the biology of Fibroblast Activation Protein (FAP), which is highly expressed in cancer-associated fibroblasts (CAF) across many tumour types. Representatives from academia and industry will take a deep dive into the topic of FAP, its history and role in the biology of disease, the current state of research, and future applications in both diagnostics and therapeutic areas.
AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using Avacta's pre|CISION technology so that it is activated by FAP, predominantly in the tumour, with the aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of the drug. Avacta's presentation, to be given by Dr Fiona Maclaughlin, Chief Scientific Officer of the Therapeutics division, will highlight the pre-clinical development of AVA6000.
No new information will be shared as part of the presentation.
Title: Pre-clinical Development of AVA6000 - a FAP targeted chemotherapeutic agent in Phase I
Day/Date: Saturday, 5 November 2022
Time: 17:30 - 17:45 CET
Session number: VI
As below. A couple of weeks from now should be confirmed as done.
The Acquisition is conditional on the Company being in receipt of not less than £45 million from the Convertible Bond Offering before 6.00 pm on 14 November 2022. The initial cash consideration for the Acquisition is £24 million, payable on completion, on a debt-free/cash-free basis and subject to customary working capital adjustments. The earn-out consideration of 50% of gross margin on sales exceeding £2 million per annum of Launch Diagnostics' COVID-19 related products is payable in respect of each of the next three years, which an overall cap of £13 million (in aggregate) over that period.
Funnily Doctor, I always thought the ex China was the right benchmark called, plus inflation of course. Our man was spot on. At times I’ve had the feeling that he may have underestimated but I’d go with it for a fire sale.
Good luck all, amazing times ahead.
£240, might top slice a bit at £220 ;)
No, not active on Twitter and also not a Gunner
Fair summary Donald. From my standpoint, I’d be in for a longer haul. I’ve stuck for some time and keen so see it through longer. I also get the feeling it’s in better hands with the Avacta team for longer.
I was surprised and impressed by their announcements this week. So many big players on board now.
I think you’re right and ultimately will end up in a big pharma but maybe not just yet. I think a fully proved platform is worth many tens of billions and needs to be taken further, for patient therapy reasons aswell as commercial ones.
It’s an interesting view Donald and conceivable. The question is of course about what stage and when is the optimum. There’s some way to go to reach that tipping point in terms of what it’s worth. From what we know, it’s too early to realise the true value of the platform. It’s de-risking as each month goes by and the value will be matching that accordingly.
I’d be surprised if Susquehanna/Heights don’t know a bit more than most Re the Therapeutics progress.
It feels right being associated with winners who get more right than wrong.
The more and more I think about it, the better it looks.
I tend to agree as well that it does help provide some cover from a low ball T/O and may see us through to a far bigger business than we might have dreamt.
Great day’s business indeed. It feels like we’ve picked up so much for virtually nothing. All good and no downsides. Big applause for a v professional job Avacta.